Get the Stockscreener App
148.77
1.38%
2.03
After Hours:
149.00
0.23
+0.15%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $148.77, with a volume of 4.57M.
It is up +1.38% in the last 24 hours and up +15.05% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$146.74
Open:
$146.6
24h Volume:
4.57M
Relative Volume:
0.62
Market Cap:
$184.47B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
20.24
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
+3.72%
1M Performance:
+15.05%
6M Performance:
+1.12%
1Y Performance:
+30.33%
1-Day Range:
$145.58
$148.94
1-Week Range:
$143.19
$148.97
52-Week Range:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
148.77 | 177.86B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,233.66 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
273.14 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.79 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
156.45 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
159.98 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock - Investing.com
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stock By Investing.com - Investing.com UK
Gilead Sciences (NASDAQ:GILD) Director Sells 5,000 Shares of Stock - MarketBeat
Gilead Sciences (GILD) director sells 5,000 shares near $146 - Stock Titan
Portfolio Design Labs LLC Takes $1.29 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
PCM Encore LLC Buys Shares of 7,399 Gilead Sciences, Inc. $GILD - MarketBeat
Vise Technologies Inc. Takes $15.17 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
14,265 Shares in Gilead Sciences, Inc. $GILD Purchased by OVERSEA CHINESE BANKING Corp Ltd - MarketBeat
Trillium Asset Management LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Allworth Financial LP Invests $5.96 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Altman Advisors Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
B. Metzler seel. Sohn & Co. AG Purchases New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ: GILD) director to sell 5,000 shares in 2026 - Stock Titan
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Gilead Sciences Stock Surges 11%, With A 7-Day Winning Spree - Trefis
Gilead Sciences Stock Climbs 11% On A 7-Day Winning Streak - Trefis
Zacks Research Expects Higher Earnings for Gilead Sciences - MarketBeat
Westport Asset Management Inc. Acquires Shares of 10,000 Gilead Sciences, Inc. $GILD - MarketBeat
Johnson Financial Group Inc. Invests $2.12 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Tocqueville Asset Management L.P. Purchases Shares of 59,933 Gilead Sciences, Inc. $GILD - MarketBeat
NewEdge Wealth LLC Takes $95.26 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Knuff & Co LLC Buys Shares of 17,641 Gilead Sciences, Inc. $GILD - MarketBeat
E Fund Management Co. Ltd. Acquires Shares of 53,836 Gilead Sciences, Inc. $GILD - MarketBeat
Edmond DE Rothschild Holding S.A. Purchases New Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Great Lakes Advisors LLC Buys Shares of 62,450 Gilead Sciences, Inc. $GILD - MarketBeat
59,974 Shares in Gilead Sciences, Inc. $GILD Purchased by Abacus FCF Advisors LLC - MarketBeat
Foster & Motley Inc. Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Diversify Advisory Services LLC Invests $1.82 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy? - Yahoo Finance
Gilead SciencesGISStock Price & News - The Motley Fool
Publicis wins Gilead Sciences' US media account - Ad Age
Gilead Sciences Inc Stock (GILD) Moved Up by 3.66% on Aug 19: A Full Analysis - TradingKey
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares - GuruFocus
Zacks Research Forecasts Higher Earnings for Gilead Sciences - MarketBeat
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up? - The Motley Fool
Meeder Advisory Services Inc. Invests $4.42 Million in Gilead Sciences, Inc. $GILD - MarketBeat
M. Kulyk & Associates LLC Buys New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Pallas Capital Advisors LLC Invests $940,000 in Gilead Sciences, Inc. $GILD - MarketBeat
Great Lakes Advisors LLC Makes New $127.25 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
13,735 Shares in Gilead Sciences, Inc. $GILD Purchased by Empirical Asset Management LLC - MarketBeat
840,400 Shares in Gilead Sciences, Inc. $GILD Purchased by Danske Bank A S - MarketBeat
Gilead Sciences Insider Sold Shares Worth $3,853,908, According to a Recent SEC Filing - marketscreener.com
Gilead Sciences CFO Andrew Dickinson sells $415k in shares - Investing.com
Andrew Dickinson Sells 3,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock - MarketBeat
Gilead Sciences chief comm & corp aff officer sells $3.85m stock - Investing.com
Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Stock - MarketBeat
Gilead (NASDAQ: GILD) CFO sells shares under 10b5-1 plan - Stock Titan
Gilead (NASDAQ: GILD) CCO sells 28,000 shares under 10b5-1 plan - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.2% but GF Value Says Overv - GuruFocus
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Is Gilead's Expanding HIV Portfolio a Growth Catalyst? - TradingView
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Gilead Sciences Inc Stock (GILD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bluestone Jeffrey | Director |
Aug 20 '26 |
Sale |
145.02 |
5,000 |
725,078 |
10,066 |
2.15%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):